Galera Therapeutics, INC. (GRTX) — 8-K Filings

8-K Filings (19)

• 8-K Filing — Apr 9, 2026
• Galera Therapeutics Files 8-K Report — Apr 3, 2026 Risk: low
  On April 3, 2026, Galera Therapeutics, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant bu
• Galera Therapeutics Enters Material Definitive Agreement — Oct 27, 2025 Risk: medium
  On October 21, 2025, Galera Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive
• Galera Therapeutics Enters Material Definitive Agreement — Oct 21, 2025 Risk: medium
  On October 21, 2025, Galera Therapeutics, Inc. filed an 8-K report to disclose the entry into a material definitive agreement. The filing does not provide speci
• Galera Therapeutics Enters Material Definitive Agreement — Sep 3, 2025 Risk: medium
  On August 27, 2025, Galera Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreement,
• Galera Therapeutics Files 8-K — Apr 2, 2025 Risk: medium
  On March 31, 2025, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also include
• Galera Therapeutics Files 8-K on Shareholder Vote Matters — Feb 25, 2025 Risk: medium
  Galera Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on matters submitted to a vote of security holders as of February 24, 2025. The filing in
• Galera Therapeutics Files 8-K on Key Corporate Events — Dec 31, 2024 Risk: medium
  On December 30, 2024, Galera Therapeutics, Inc. filed an 8-K report detailing several significant events. These include the entry into a material definitive agr
• Galera Therapeutics Files 8-K — Dec 20, 2024 Risk: low
  On December 20, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated
• Galera Therapeutics Files 8-K on Shareholder Vote Matters — Oct 18, 2024 Risk: low
  Galera Therapeutics, Inc. filed an 8-K on October 18, 2024, reporting on a submission of matters to a vote of security holders. The filing indicates that the co
• Galera Therapeutics Faces Nasdaq Delisting — Sep 4, 2024 Risk: high
  Galera Therapeutics, Inc. filed an 8-K on August 31, 2024, to report its failure to meet the continued listing standards of the Nasdaq Capital Market. The compa
• Galera Therapeutics Appoints New Chief Medical Officer — Aug 14, 2024 Risk: low
  Galera Therapeutics, Inc. announced on August 14, 2024, that its Board of Directors has appointed Dr. Jonathan P. Saffer as Chief Medical Officer. Dr. Saffer, w
• Galera Therapeutics Files 8-K for Regulation FD Disclosure — Aug 8, 2024 Risk: medium
  On August 8, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material non-public infor
• Galera Therapeutics Announces Leadership Changes and New Director Appointments — Jun 7, 2024 Risk: medium
  Galera Therapeutics, Inc. announced on June 4, 2024, the departure of its Chief Medical Officer, Dr. Norman Greenberg. The company also reported the election of
• Galera Therapeutics Faces Nasdaq Delisting Warning — Jun 3, 2024 Risk: high
  Galera Therapeutics, Inc. announced on May 31, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The co
• Galera Therapeutics Files 8-K — May 13, 2024 Risk: low
  On May 13, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 45 Liberty Blvd, S
• Galera Therapeutics Files 8-K: Material Agreements and Shareholder Rights — May 3, 2024 Risk: medium
  On May 2, 2024, Galera Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in this 8-K filing. The filing also
• Galera Therapeutics Files 8-K on Financials — Mar 28, 2024 Risk: low
  On March 28, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• Galera Therapeutics Faces Delisting Notice — Mar 27, 2024 Risk: high
  Galera Therapeutics, Inc. filed an 8-K on March 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX